Navigation Links
2.5v Ophthalmic Diagnostic Set

Products2.5v Ophthalmic Diagnostic Set
Company Welch Allyn Medical Products
Item 2.5v Ophthalmic Diagnostic Set
Features 
  • The retinoscope's continuously rotating external focusing sleeve is easy to grip and manipulate regardless of hand size.
  • The magnetic fixation cards make dynamic retinoscopy easy to perform.
  • The retinoscope and ophthalmoscope come with halogen light for bright, consistent, long-lasting illumination and brow rests to prevent scratching of eyeglasses.
  • Ophthalmoscope has 6 apertures for general and specialist use, and 28 lenses with -25 to +40 diopters for better resolution.
  • The handle comes with a rheostat with on-off switch for variable power.
  • It's ideal for field or off-site examinations where standard outlets are not available.
    • Description Our Ophthalmic Diagnostic Sets offer everything an eye care specialist needs. Complete your set with your choice of ophthalmoscope, retinoscope, handle, and case.
    Info Welch Allyn Medical Products
    Customer Service: (800) 535-6663
    Web site: http://www.welchallyn.com/medical/

    Related medicine products :

    1. 2.5V Ophthalmic BETA 200 Pro
    2. Katena Ophthalmic Burr
    3. Ophthalmic Burr
    4. Lpulsa SYL9000 Ophthalmic Yag Laser
    5. FML* Ophthalmic Suspension
    6. PRED FORTE* Ophthalmic Suspension
    7. MAXITROL Ophthalmic Oinent
    8. MAXITROL Ophthalmic Suspension
    9. CORTISPORIN* Ophthalmic Suspension
    10. Hydraulic Ophthalmic Stretcher For Eye Surgery
    11. Ophthalmic Surgery Stretcher
    ...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
    ...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
    ...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
    ...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
    Medicine Products:
    (Date:7/18/2008)...est weight loss yields significant health benefits...oalition -- a group of,experts on overweight and o...dia to reevaluate the way they report on weight lo...ed news coverage and editorial content that,leads ... dieters if they,lose an enormous amount of weight...
    (Date:7/18/2008)...n Is Not What America Signed Up For, WASHINGTON, ... McCain,s,top economic advisor, Phil Gramm, echoed...s were "psychological" by saying Americans are in ... "nation of whiners." While McCain,distanced himse...ard as,McCain,s top economic adviser. Now, John Mc...
    (Date:7/18/2008)... Behavior spanning the wide spectrum of the animal...rnational Behavioral Ecology Congress, hosted by t...n Aug. 10 -14, 2008, at Cornell University in Itha...e congress will feature plenary sessions on: , ...olutionary biology, Yale University, on "When Theo...
    (Date:7/18/2008)...ren preventive antibiotics within one hour before ...sk for serious infections after the surgery, sugge...ugust issue of Pediatric Infectious Disease Journ...en who received antibiotics outside of the golden ...ely to develop serious infections at the surgery s...
    Breaking Medicine News(10 mins):Health News:Medical Experts Call on Media to Rethink Coverage of Weight Loss 2Health News:Medical Experts Call on Media to Rethink Coverage of Weight Loss 3Health News:DNC: McCain Watch: The Economy 2Health News:DNC: McCain Watch: The Economy 3Health News:Averting postsurgical infections in kids: Give antibiotics within hour before first incision 2
    ...for resistance to food allergy has been identified...s currently no way to treat food allergy and the ... avoid certain foods and make sure they have injec...led by Dr Claudio Nicoletti at the Institute of Fo...
    ...ficials of DelSite Biotechnologies, Inc., a wholly... said the company's novel powder-based vaccine de...les that delay influenza pandemic preparedness whi...tions for the Control of Influenza VI Conference" ...
    ...nsylvania, Shire plc announced today that it has s...A) to the U.S. Food and Drug Administration (FDA) ...the treatment of Attention Deficit Hyperactivity D...cation is subject to a 10-month FDA review period....
    ...of Wales has proposed that artists are important t...Wales to help create better environments for pati... for all new hospital that is going to come up in ...order to ensure that the patients morale is booste...
    Other Medicine News:Health News:Potential Target for Allergy Therapy 2Health News:DelSite Working Toward Solving Delivery of Influenza Vaccine in Pandemic Situations 2Health News:DelSite Working Toward Solving Delivery of Influenza Vaccine in Pandemic Situations 3Health News:VYVANSE(TM) Drug for the Treatment of ADHD in Adults 2Health News:Art in Hospitals to Enhance Patient Care 2
    (Date:7/17/2008)... FREISING-WEIHENSTEPHAN and JENA, Germany, July 17...ompany developing Anticalins(R), a novel,class of ...otech GmbH, a,full-service contract manufacturer o...icant milestone in the development of Pieris, PRS-... developed PRS-050 as a next generation VEGF antag...
    (Date:7/17/2008)...econd instance where survival increase is observed...receiving Tavocept in conjunction with standard ...n survival increase of 6.5 months seen for patient...pe of lung cancer, SAN ANTONIO, July 17 /PRNewswi...ik") today announced that patients with adenocarci...
    (Date:7/16/2008)... DANBURY, Conn., July 16 /-...ts two pivotal Phase III VIAject(TM) clinical,tria...isit on July 14,2008. Results of the full trial w...tion at the European Association for the Study of ...at a later appropriate scientific forum., Biodel ...
    (Date:7/16/2008)... Raptor to Support Phase 2a Clinical Tria...rstCall/ -- Raptor,Pharmaceuticals Corp. ("Raptor"...ay announced the execution of a collaboration agre...ifornia, San Diego ("UCSD") to,include a Phase 2a ...ration,of cysteamine bitartrate ("Cysteamine") in ...
    Breaking Medicine Technology:Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050 2BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial 2BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial 3BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial 4Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program 2Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program 3Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program 4Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program 5Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 2Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 3Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 4Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 5Immucor Announces Fiscal Year 2009 Revenue and Earnings Guidance 5813 1Immucor Announces Fiscal Year 2009 Revenue and Earnings Guidance 5813 2Immucor Announces Fiscal Year 2009 Revenue and Earnings Guidance 5813 3Heart Patients More Likely to Adopt Healthy Habits in 3 Year Program Led by Cardiac Rehabilitation Experts Mayo Clinic Research Shows 2327 1Heart Patients More Likely to Adopt Healthy Habits in 3 Year Program Led by Cardiac Rehabilitation Experts Mayo Clinic Research Shows 2327 2Heart Patients More Likely to Adopt Healthy Habits in 3 Year Program Led by Cardiac Rehabilitation Experts Mayo Clinic Research Shows 2327 3Heart Patients More Likely to Adopt Healthy Habits in 3 Year Program Led by Cardiac Rehabilitation Experts Mayo Clinic Research Shows 2327 4Cooling May Not Help Injured Brains in Children 21089 1Cooling May Not Help Injured Brains in Children 21089 2Cooling May Not Help Injured Brains in Children 21089 3Verizon Executive Urges Congress to Pass Health Care IT Legislation 21084 1Verizon Executive Urges Congress to Pass Health Care IT Legislation 21084 2Verizon Executive Urges Congress to Pass Health Care IT Legislation 21084 3Verizon Executive Urges Congress to Pass Health Care IT Legislation 21084 4
    ... Pain on Sleep Interference, INDIANAPOLIS, May 03,... analysis of three studies suggest that in patient...abetic peripheral neuropathy,who are treated with...verage daily pain and night pain severity were ass...than in those patients,taking sugar pill. Results ...
    ...2007 /PRNewswire-FirstCall/ --,Phosphagenics Limit...ends to initiate a Phase 1b clinical trial to demo...rmulation of its transdermal,insulin product, TPM-...ial is expected to commence in the second quarter ...s a novel "needle-free",way of administering insul...
    Other Medicine Technology:Data Suggest Cymbalta Reduced Severity of Night Pain in Patients,with Diabetic Nerve Pain 2Data Suggest Cymbalta Reduced Severity of Night Pain in Patients,with Diabetic Nerve Pain 3Data Suggest Cymbalta Reduced Severity of Night Pain in Patients,with Diabetic Nerve Pain 4Data Suggest Cymbalta Reduced Severity of Night Pain in Patients,with Diabetic Nerve Pain 5Data Suggest Cymbalta Reduced Severity of Night Pain in Patients,with Diabetic Nerve Pain 6Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical,Trial in Second Quarter 2